EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 93 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $270,271 | -59.0% | 886,134 | -5.4% | 0.00% | – |
| Q2 2023 | $659,736 | -73.8% | 937,125 | -66.6% | 0.00% | – |
| Q1 2023 | $2,517,635 | -25.3% | 2,807,041 | -1.7% | 0.00% | – |
| Q4 2022 | $3,369,714 | -83.6% | 2,855,690 | +4.4% | 0.00% | -100.0% |
| Q3 2022 | $20,600,000 | +18.6% | 2,735,658 | -0.8% | 0.00% | 0.0% |
| Q2 2022 | $17,367,000 | -14.4% | 2,756,733 | +12.8% | 0.00% | 0.0% |
| Q1 2022 | $20,287,000 | +58.1% | 2,444,264 | -1.2% | 0.00% | – |
| Q4 2021 | $12,835,000 | -22.3% | 2,472,964 | -0.0% | 0.00% | – |
| Q3 2021 | $16,526,000 | -21.7% | 2,474,139 | -0.1% | 0.00% | -100.0% |
| Q2 2021 | $21,097,000 | -5.1% | 2,476,122 | -1.4% | 0.00% | 0.0% |
| Q1 2021 | $22,222,000 | -23.9% | 2,510,932 | +5.7% | 0.00% | 0.0% |
| Q4 2020 | $29,192,000 | +59.7% | 2,375,286 | +5.7% | 0.00% | 0.0% |
| Q3 2020 | $18,283,000 | -3.2% | 2,246,190 | +14.2% | 0.00% | 0.0% |
| Q2 2020 | $18,889,000 | +49.0% | 1,967,576 | +5.5% | 0.00% | 0.0% |
| Q1 2020 | $12,676,000 | -55.0% | 1,864,188 | -1.3% | 0.00% | 0.0% |
| Q4 2019 | $28,157,000 | +54.2% | 1,889,692 | +6.1% | 0.00% | 0.0% |
| Q3 2019 | $18,262,000 | -0.4% | 1,781,600 | +3.0% | 0.00% | 0.0% |
| Q2 2019 | $18,330,000 | +189.5% | 1,729,161 | +281.9% | 0.00% | – |
| Q1 2019 | $6,331,000 | +33.0% | 452,753 | -3.4% | 0.00% | – |
| Q4 2018 | $4,761,000 | +76.7% | 468,678 | +108.6% | 0.00% | – |
| Q3 2018 | $2,695,000 | +0.7% | 224,650 | +2.4% | 0.00% | – |
| Q2 2018 | $2,675,000 | +235.6% | 219,278 | +171.0% | 0.00% | – |
| Q1 2018 | $797,000 | +98.3% | 80,912 | +181.0% | 0.00% | – |
| Q4 2017 | $402,000 | +29.7% | 28,798 | +2.5% | 0.00% | – |
| Q3 2017 | $310,000 | +37.2% | 28,090 | -2.2% | 0.00% | – |
| Q2 2017 | $226,000 | -89.4% | 28,728 | -84.5% | 0.00% | – |
| Q1 2017 | $2,126,000 | +106200.0% | 185,645 | +123663.3% | 0.00% | – |
| Q4 2016 | $2,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q3 2016 | $2,000 | -33.3% | 150 | 0.0% | 0.00% | – |
| Q2 2016 | $3,000 | – | 150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |